Re: [NMusers] Separation of the PK parameters for mixed endogenous and exogenous substances.

Dear Karam This is a simple example we used modelling endogenous and exogenous IGF-1: https://pubmed.ncbi.nlm.nih.gov/23793696/ BW Joe On 6 Oct 2024, at 09:34, karam alali wrote:  You don't often get email from ph.kar...@gmail.com. Learn why this is important

[NMusers] UCL-GSK PhD studentship in pharmacometrics

Dear NMUsers, Please circulate the following opportunity to anyone interested in a PhD in Pharmacometrics/Machine Learning: https://www.ucl.ac.uk/work-at-ucl/search-ucl-jobs/details?jobId=23522&jobTitle=4-Year+PhD+studentship%3A+Towards+efficient+drug+development+modelling+with+machine+learning

[NMusers] PKUK 10-12th November

> The next PKUK meeting will take place in Canterbury on 10-12th > November. A hybrid online/face-to-face meeting is planned with sessions > on CNS, Complex Pharmacology, Vaccine development and the open session > for submitted abstracts. > > A reduced fee for attendees via Zoom is available, but

[NMusers] Postdoc/senior postdoc in SARS-CoV-2 viral dynamics

Postdoc/senior postdoc in SARS-CoV-2 viral dynamics modelling to inform antiviral drug development. Involves analysing Phase II trial and clinical observational data. Includes a placement at Pfizer and engagement with national therapeutics task force. Closing date 12th June 2021: https://www.j

[NMusers] Postdoctoral Fellow UCL

Dear NMUsers, We have recently advertised a postdoctoral position. This role will provide pharmacometrics input to a Wellcome trust funded project to use machine learning for predicting pharmacokinetics. The project is a collaboration with computer scientists at UCL and Benevolentai and the su

RE: [NMusers] Strange PRED prediction in SAEM with M3 BQL handling

Dear Cornelis, Please have a look at the following for how to visualise NPDEs with a "PRED" for BLQ data: Nguyen THT, Comets E. Mentre ́ F. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic mode

RE: [NMusers] Why should we avoid using micro rate constants?

th Antimicrobial Pharmacist, Great Ormond Street Hospital Honorary Senior Lecturer, St George's University of London Tel: +44(0)207 905 2370 Mobile: +44(0)7970 572435 From: owner-nmus...@globomaxnm.com [owner-nmus...@globomaxnm.com] on behalf of STANDING,

RE: [NMusers] Why should we avoid using micro rate constants?

Dear Sumeet, If you are assuming a distribution for your parameters (e.g. log-Normal p = theta * exp(eta)) then it might matter if you use rate constants versus clearances and volumes. In general, if you want to make the log-Normal assumption you should use clearances and volumes as there is r

[NMusers] Postdoctoral Fellowship, London

We have a postdoctoral position open to work on PKPD in paediatric infectious diseases, closing date 6th November. Please see the link below for more details: https://www.jobs.ac.uk/job/BNE904/research-fellow-in-pharmacometrics Joseph F Standing MRC Fellow, UCL Institute of Child Health Antimi

[NMusers] PKUK 21-23rd November

The next PKUK meeting will take place in Manchester on 21-23rd November. There will be sessions on Artificial Intelligence, Gene therapy, Disease modelling and Regulatory in addition to the Open Session. The abstract deadline has been extended to 5th October. PhD students who are chosen to giv

RE: [NMusers] [Suggest] NONMEM adds UTF-8 support for csv files

Dear Mark, Here is another workaround: abandon the use of Microsoft Excel (and all possible Microsoft products) since this behaviour - new "improved" version that you paid for - actually makes your life harder. I have also encountered problems with Excel helpfully changing date format or time

[NMusers] PhD studentship UCL/BBK/AZ

Please see a link to a PhD studentship entitled: Extrapolation of haematopoiesis dynamics following cytotoxic insult to personalise paediatric drug development. https://www.ucl.ac.uk/mrc-dtp/prospective-students/case-studentships/ The project is funded by the UK Medical Research Council so unfo

RE: [NMusers] Allometric scaling of renal clearance with estimated glomerular filtration rate

TANDING, Joseph (GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST) wrote: Dear Rob, Why do you want to use a model to predict the value of a covariate to add into your model? Apart from glomerular filtration rate, what other situations would you do this? I'm not sure what y

RE: [NMusers] Allometric scaling of renal clearance with estimated glomerular filtration rate

Dear Rob, Why do you want to use a model to predict the value of a covariate to add into your model? Apart from glomerular filtration rate, what other situations would you do this? Unless I was trying to do some fancy separation of renal and non-renal clearance, I would simply ignore the fact

[NMusers] ISoP Local Event, London

Dear NMUsers, The first ISoP SE England Local Event will be held on Wednesday 13th Dec at 4pm at the UCL Institute of Child Health. The topic of the meeting is: Machine Learning in Pharmacometrics. Afterwards there will be a networking event. Registration is free, please see the eventbrite l

[NMusers] PKUK 30th Anniversary first announcement

This year will be the 30th official PKUK meeting, and we will be going back to the venue of that original meeting. Thankfully the Abbey Hotel has been thoroughly modernised and brought up-to-date, and our themed session "30 years of PKUK" featuring speakers from that original meeting will highli

[NMusers] PKUK 2016

PKUK will be taking place in London from 9-11 November 2016. We have the following sessions planned: Experimental design Antimicrobial clinical pharmacodynamics Immunotherapy Absorption Open session The conference fee covers 2 nights hotel, and all meals. Abstract deadline for the open session/

RE: [NMusers] Problem of STS in NONMEM

Dear Anyue, I think you are trying to make a short-cut to getting individual parameter estimates in one go. It maybe possible for someone more intelligent than me, but can I suggest just doing it the long way round by fitting the model to each individual in turn. Something like this should wo

RE: [NMusers] Incomplete circles drawn in VPC plotted using R scripts generated by PsN

I think it is a problem with R making pdfs. Workaround: try using tiff() or png() instead - then you can save the image as a pdf. Joe From: owner-nmus...@globomaxnm.com [owner-nmus...@globomaxnm.com] On Behalf Of Kajsa Harling [kajsa.harl...@farmbio.uu.

[NMusers] Child Health PhD studentship available

Funded PhD studentships for the academic year 2016/17 are now open for application at University College London Institute of Child Health (closing date 13th November 2015). Please see the link below for more information on possible projects/how to apply: https://www.ucl.ac.uk/ich/education/fell

[NMusers] RE: Modeling accelerated phase of malignancy

Dear Mark, I think one problem might be the distributioal assumption on NTLAG in that if you have outlying individuals with early/late lag you may need to think of a sensible transformation for the ETA or there might be no obvious one. Do all the subjects go into the exponential phase or might

RE: [NMusers] RE: Dataset coding for baseline endogenous substance

Dear Brady, If you have a model for the endogenous substance/biomarker that has a steady state then you can just write the baseline as a function of the model parameters. Very simple turnover example - see Rao A. BMJ Open. 2013 May 28;3(5)) IGF-1 baseline is given by Ksyn/Kout. For more compl

[NMusers] Job posting

I am posting this on behalf of Terry Shepard. Terry is leaving her job at the MHRA, and as a high compliment they are replacing her with two people! Please see links below, and contact Terry directly (terry.shep...@mhra.gsi.gov.uk) for more information. LD256 Senior Pharmacokinetics Assessor

[NMusers] Antimicrobial Pharmacometrician Job in London

Please see in the link below an advert for a pharmacometrician with an interest in antimicrobial stewardship at Imperial College. The London Pharmacometrics Interest Group has informal links with these people, so the post-holder would be welcome to join our weekly meetings also. Advert: http:

[NMusers] RE: Using MCP-MOD in dose finding for Phase 3

Dear Nele, One advantage of the biologically blind multiple model approach in Phase 2B is that it shifts the blame from the pharmacologist to the statistician when you get the wrong dose in Phase 3. Agree that you should be concerned when people want to use use dose rather than PK (not symmetr

RE: [NMusers] OMEGA matrix

Dear Pavel, To answer your question I suggest you go on Bob Bauer's NONMEM 7 course. The understanding I gleaned from that course (which I think was enhanced by the excellent wine we had at lunch in Alicante) was that with appropriate MU parameterisation there is virtually no computational dis

RE: [NMusers] SAEM and IMP

Dear Emmanuel and Pavel, Further to Bob's answer, recall also that delta OFV in the likelihood ratio test is only asymptotocaily chi squared distributed,and this is not the only reason why you should not get too hung up on OFV to help choose your models. For example, Lavielle 2010 in Biometric

RE: [NMusers] Simulate simultaneous zero and first order absorption

Dear Justus, I agree with Navin that the first dose is ignored because the system is reset by the second dose SS/II. Navin's solution however I think will only set the CMT1 dosing as being at steady state and the CMT2 dose will be the first. When we encountered a similar problem the inelegant

[NMusers] Postdoctoral position in London

Dear NMUsers, We have recently opened a postdoc position to work primarily on an applied paediatric study, but also to join the activities of the UCL pharmacometrics group. The closing date for applications is 13th November. More details can be found here: http://www.jobs.ac.uk/job/AHM229/re

RE: [NMusers] Time-varing covariate and renal function as a covariate

, Joe From: owner-nmus...@globomaxnm.com [owner-nmus...@globomaxnm.com] On Behalf Of J.H.Proost [j.h.pro...@rug.nl] Sent: 04 September 2013 11:42 To: Standing Joseph (GREAT ORMOND STREET HOSPITAL FOR CHILDREN NHS FOUNDATION TRUST); Matt Hutmacher; '

RE: [NMusers] Time-varing covariate and renal function as a covariate

Dear Matt, Your first hypothetical scenario is an argument not to use CRCL because as you point out, weight is entering the model twice: once to predict renal function and once to scale for size. Other problems of using models that predict CLCr (when really you are interested in your drug CL,

RE: [NMusers] Minimisation problem...

Dear Gavin, It would seem the first place to start is with your structural model. A 3rd order polynomial with IIV on the parameters should give a perfect fit to every subject subject with <= 3 sampling points. How about a more mechanistic approach? It sounds like you are modelling the change

RE: [NMusers] The theory of relativity for CL and V...

Dear Paolo, I think you are right to report disposition parameters and F separately and then in the text calculate CL/F and V/F values for comparison with literature, but I agree with Rob that a mechanistic 'hepatic' model would be worth a try. If you are concerned about the validity of literat

RE: [NMusers] VD as a fraction of another VD

Dear Orlando, I think Martin has put the matter to bed in terms of how you ought to parameterise your model. One more thing to consider is that depending how rich are your data, your model might start getting over parametrised. In this case fixing volumes to known physiological values is a go